Berto Acquisition 3Q 2026: Net income $1.33M — 10-Q Summary

Berto Acquisition reported a 57.9% YoY drop in net income to $1.33M due to higher expenses, including merger costs, and lower investment income. The SPAC has no operating revenue and continues searching for a business combination. As of Q3 2026, it had $49K in cash and a $3.7M working capital deficit.

Original reporting
Published Nov 13, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Berto Acquisition 3Q 2026: Net income $1.33M — 10-Q Summary — source image
Decision brief

The 30-second read

$TACOBearishLow
01

Why it matters

The filing highlights ongoing financial strain and the need for a merger to generate revenue.

02

Market read

Micro‑cap SPAC earnings with negative net income and low cash are typically bearish for the stock.

03

What to watch

Potential hidden value in the trust account assets or upcoming merger announcements.

Relevance 5/10Novelty 5/10Timing: post‑market filing

Background

Berto Acquisition Corp is a SPAC that has not yet completed a business combination and continues to search for targets.

Company-level read

Ticker impact

$TACOBearishMedium confidence
Context

Berto Acquisition Corp filed its 10‑Q reporting Q3 net income of $1.33 M, a 57.9% YoY decline and ongoing SPAC search.

Expected impact

likely pressure as investors price in the lack of operating revenue and cash shortfall

Evidence & confidence

Micro‑cap SPACs with negative earnings and minimal cash typically see share weakness.

Market effects

Limited impact; reflects broader SPAC market challenges.

Minimal; confined to U.S. micro‑cap investors.

Low; no broader macro or sector ripple.

Counterpoint

If the SPAC secures a high‑value merger, the current loss could be a short‑term dip.

Key entities

  • Berto Acquisition Corp

    SPAC listed under ticker TACO.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.